Merck and Moderna's personalized mRNA melanoma therapy hit its Phase 3 goals. What the trial showed, how strong the evidence is, and why it's not here yet.
Health is complicated. But the way you interact with the healthcare system doesn't have to be. This is where we share what we know, who we're building with, and why it matters.